Psy188 - Use of Managed Entry Agreements in Inflammatory Disorders Among Key Health Technology Assessment Agencies

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2762
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Scientific Methodology and Practical Use of Managed Entry Agreements for Innovative Medicines in System of Health Technology Assessment in Ukraine

Farmatsevtychnyi zhurnal
2019English

What Principles Should Govern the Use of Managed Entry Agreements?

International Journal of Technology Assessment in Health Care
Health Policy
2011English

Adoption of Managed Entry Agreements in Established and Emerging Markets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Php353 - Romanian Experience With Managed Entry Agreements for Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Managed Entry Agreements (MEA): Analysis of the Current Situation in Middle East and North Africa

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Php249 - Are Traditional Managed Entry Agreements Suitable for Potentially, Curative Gene/Cell Therapies?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Intercontinental Links Among Health Technology Assessment Organizations

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Potential Use of Routine Databases in Health Technology Assessment

Health Technology Assessment
MedicineHealth Policy
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy